Diamond Score

BioCryst Pharmaceuticals, Inc.

Healthcare · Biotechnology · $2.0B market cap

Overlooked Strong Foundation

$9.67

Updated 2026-04-11

Discovery Thesis

AI-generated catalyst thesis will be available after transcript analysis. The quantitative signals below highlight why this company appears to be at an inflection point.

Quantitative summary: Margin expanding 4Q, ROIC improving.

Three-Pillar Score Breakdown

Overlooked

25% weight

Inflection

45% weight

Foundation

30% weight

6-Month Price Action

Inflection Signals

Revenue Acceleration

4Q data

QoQ growth: 0.1064 → 0.1224 → -0.0242 → 1.5506

Margin Expansion

4Q streak

Margins: 0.1459 → 0.1823 → 0.1856 → 0.6405

ROIC Trend

72.1%

0.0024 → 0.0828 → 0.1001 → 0.7206

Insider Buying

0 buys (90d)

Earnings Streak

1Q beats

PEG Ratio

—

Debt Paydown

—

Relative Strength (6M)

32.4%

Earnings Surprise Streak

2026-02-26

+1500.0%

$1.12 vs $0.07

Foundation — Business Quality

Free Cash Flow (TTM)

$0M

Debt / Equity

999.00x

Revenue Growth (YoY)

94.1%

ROIC

72.1%

Overlooked — Why the Market Hasn't Noticed

Analyst Coverage

3 analysts

Very low coverage

Market Cap

$2.0B

Sweet spot ($2-10B)

ETF Inclusion

Not in top ETFs

← Back to all diamonds